Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
Filings by filing date
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9620 Medical Center Drive, Suite 300 BEIJING BEJ 100025 |
Tel: | N/A |
Website: | www.casipharmaceuticals.com |
IR: | See website |
Key People | ||
Wei-Wu He Chairman of the Board, Chief Executive Officer | Wei Zhang President, Principal Financial Officer | Chunhua Wang Chief Operating Officer |
Huang Hai Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China | Alexander A. Zukiwski Executive Vice President, Chief Medical Officer | Kun Qian Vice President, Controller |
Wei Gao General Counsel | Fuqiang Zhang Chief Commercial Officer |
Business Overview |
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company's Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets. |
Financial Overview |
For the fiscal year ended 31 December 2023, CASI Pharmaceuticals Inc revenues decreased 21% to $33.9M. Net loss applicable to common stockholders decreased 34% to $27M. Revenues reflect Sublicensing revenue from a related part decrease from $5M to $0K, Product sales decrease of 11% to $33.9M, Lease income from a related party decrease from $60K to $0K. Lower net loss reflects Impairment of intangible assets decrease from $8.7M (expense) to $0K. |
Employees: | 176 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $30.29M as of Dec 31, 2023 |
Annual revenue (TTM): | $33.88M as of Dec 31, 2023 |
EBITDA (TTM): | -$25.28M as of Dec 31, 2023 |
Net annual income (TTM): | -$26.96M as of Dec 31, 2023 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | $0.14M as of Dec 31, 2023 |
Shares outstanding: | 13,401,375 as of Mar 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |